Tumor Necrosis Factor-alpha - or Lipopolysaccharide-induced Expression of the Murine P-selectin Gene in Endothelial Cells Involves Novel kappa B Sites and a Variant Activating Transcription Factor/cAMP Response Element*

Junliang Pan, Lijun Xia, Longbiao Yao, and Rodger P. McEverDagger

From the Departments of Medicine and Biochemistry & Molecular Biology, W. K. Warren Medical Research Institute, University of Oklahoma Health Sciences Center, and Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Tumor necrosis factor-alpha (TNF-alpha ) or lipopolysaccharide (LPS) increases expression of the P-selectin gene in murine, but not in human, endothelial cells. These mediators augment expression of a reporter gene driven by the murine, but not the human, P-selectin promoter in transfected endothelial cells. The regions from -593 to -474 and from -229 to -13 in the murine P-selectin promoter are required for TNF-alpha or LPS to stimulate reporter gene expression. Within these regions, we identified two tandem kappa B elements, a reverse-oriented kappa B site and a variant activating transcription factor/cAMP response element (ATF/CRE), that participate in TNF-alpha - or LPS-induced expression. The tandem kappa B elements bound to NF-kappa B heterodimers and p65 homodimers, the reverse-oriented kappa B site bound to p65 homodimers, and the variant ATF/CRE bound to nuclear proteins that included activating transcription factor-2. Mutations in each individual element eliminated binding to nuclear proteins and decreased by 20-60% the TNF-alpha - or LPS-induced expression of a reporter gene driven by the murine P-selectin promoter in transfected endothelial cells. Simultaneous mutations of all elements further decreased, but did not abolish, induced expression. Co-overexpression of p50 and p65 enhanced murine P-selectin promoter activity in a kappa B site-dependent manner. These data indicate that the kappa B sites and the variant ATF/CRE are required for TNF-alpha or LPS to optimally induce expression of the murine P-selectin gene. The presence of these elements in the murine, but not the human, P-selectin gene may explain in part why TNF-alpha or LPS stimulates transcription of P-selectin in a species-specific manner.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Tumor necrosis factor-alpha (TNF-alpha )1 and LPS are mediators that increase expression of many proteins in a variety of cells. Either agent stimulates endothelial cells to synthesize diverse proteins that participate in inflammation or coagulation (1, 2). These include the adhesion molecules E-selectin, vascular adhesion molecule-1, intercellular adhesion molecule-1, and mucosal addressin cell adhesion molecule-1; the cytokines IL-1, IL-6, and IL-8; and the coagulation protein tissue factor (3-10). TNF-alpha and LPS induce expression through both transcriptional and post-transcriptional mechanisms (2, 6, 7, 11). Transcriptional activation requires specific combinations of basally expressed and signal-regulated transcription factors (2, 12). The best characterized transcription factors regulated by signaling through TNF-alpha and LPS are NF-kappa B/Rel proteins and proteins activated by MAP kinases.

In mammals, the NF-kappa B/Rel family includes NF-kappa B1 (p50), NF-kappa B2 (p52), RelA (p65), c-Rel, and RelB (13). The DNA-binding forms of NF-kappa B/Rel proteins are homodimers or heterodimers that recognize decameric kappa B elements. Most kappa B elements have incomplete dyad symmetry and have a characteristic 5' to 3' orientation relative to the transcriptional start site. The prototypical NF-kappa B heterodimer (p50/p65) recognizes kappa B elements with the consensus 5'-GGGRNNYYCC-3'. However, some variant kappa B sites are recognized only by specific homodimeric or heterodimeric combinations of NF-kappa B/Rel proteins (14-17). The p65-containing dimers are retained in the cytoplasm through complex formation with Ikappa Balpha and related proteins. Upon cellular stimulation by TNF-alpha or LPS, Ikappa B-alpha is degraded. Dimers containing p65 then migrate into the nucleus and activate many genes with kappa B elements, including the gene encoding Ikappa B-alpha (18, 19). The newly synthesized Ikappa B-alpha terminates the activity of p65-containing dimers, resulting in post-inductional repression of transcription (20, 21).

TNF-alpha or LPS signals the activation of the JNK and p38 MAP kinases (22, 23), which translocate to the nucleus and phosphorylate substrates that include ATF-2 and c-Jun (24-26). ATF-2 is a member of the ATF/cAMP response element binding protein family of transcription factors; it functions as homodimers or heterodimers that recognize an 8-bp variant ATF/CRE site (5'-TGACATCA-3') (27, 28). c-Jun is a member of the AP1 family of transcription factors; it functions as homodimers or heterodimers that bind to a 7-bp AP1 site (5'-TGANTCA-3') (29). Phosphorylation of ATF-2 and c-Jun proteins enhances the abilities of dimeric complexes, notably ATF-2/c-Jun and c-Fos/c-Jun heterodimers, to activate transcription (24, 26).

The pathways for activation of NF-kappa B/Rel proteins and JNK/p38 MAP kinases are evolutionarily conserved from insects to mammals (30, 31). TNF-alpha and LPS also generally use conserved pathways to activate a specific gene. For example, the LPS response element of the tissue factor promoter contains two AP1 sites and a kappa B site that are conserved in at least four different mammals (11). TNF-alpha -induced expression of the E-selectin gene is mediated by an enhanceosome that contains three kappa B sites, a variant ATF/CRE, and four A/T-rich sequences that bind to the architectural HMG I(Y) proteins (32, 33). All these elements are required for TNF-alpha or LPS to maximally induce transcription, and they are conserved in both the human and murine E-selectin genes (34).

By contrast, TNF-alpha or LPS increases expression of the P-selectin gene in murine endothelial cells but not in human endothelial cells (35-37). In the preceding paper (38), we demonstrated that these mediators augment expression of a reporter gene driven by the murine, but not the human, P-selectin promoter in transfected endothelial cells. Furthermore, the sequences from -593 to -474 and from -229 to -13 in the murine P-selectin promoter are required for TNF-alpha or LPS to stimulate expression of the reporter gene (38). To dissect the molecular basis for this unusual species-specific gene activation event, we employed pharmacologic agents, DNA-binding experiments, transfection studies, and mutational analysis to characterize the regulatory elements and their cognate proteins that contribute to TNF-alpha - or LPS-induced expression of the murine P-selectin gene. We identified two tandem kappa B sites, a reverse-oriented kappa B site and a variant ATF/CRE, that participate in TNF-alpha - or LPS-induced expression. These elements are not present in the corresponding regions of the human P-selectin gene, which may account in part for the species-specific response of the P-selectin gene to TNF-alpha or LPS.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Reagents and Antibodies-- Recombinant human TNF-alpha and ALLN (calpain inhibitor I) were purchased from Boehringer Mannheim. PDTC, cycloheximide, anisomycin, actinomycin D, and LPS from Salmonella typhosa were obtained from Sigma. A stock solution of ALLN was made in dimethyl sulfoxide (American Type Culture Collection) at a concentration of 50 mM. Stock solutions of cycloheximide, anisomycin, and actinomycin D were made in ethyl alcohol (Quantum Chemical Co., Tuscola, IL) at a concentration of 5 mg/ml. Antibodies against p50, p52, p65, c-Rel, RelB, ATF-2, c-Jun, and c-Fos were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Expression plasmids encoding p50 or p65 were a generous gift from Dr. Craig Rosen (39).

Gel Mobility Shift Assay-- Nuclear extracts from murine bEnd.3 endothelioma cells or BAEC were prepared as described (40). Gel mobility shift assays were performed as described (15). The sequences of the oligonucleotides used in gel mobility shift assays are shown in the figures. The oligonucleotides were 5' end-labeled by [gamma -32P]ATP using T4 polynucleotide kinase.

Construction of Chimeric Luciferase Expression Vectors-- Plasmids mp1379LUC, p1379IBI, and p0LUC were described in the preceding paper (38). Plasmids mpMutkappa B, mpMutRkappa B, mpMutATF, mpMutDouble, and mpMutTriple, which carry mutations in kappa B and/or variant ATF/CRE as indicated in the text, were constructed in the following two steps. 1) The KpnI-PstI or PstI-SacI fragment in p1379IBI was replaced with respective PCR products generated according to an overlap extension protocol (41, 42). 2) The KpnI-HindIII fragment (from -1379 to -13) that carried each mutation was excised and inserted between the KpnI and HindIII sites of p0LUC. All constructs were confirmed by restriction mapping, and the fidelity of the PCR-generated cassettes was verified by sequencing.

Cell Culture, Transfection, and Stimulation-- Murine bEnd.3 cells and BAEC were cultured as described (37, 42). Preparation of plasmids, transfections and co-transfections, and luciferase assays were described previously (15). The total amount of DNA for each co-transfection was held constant at 8 µg/dish of cells by adding an appropriate amount of a plasmid with a lacZ insert driven by a cytomegalovirus promoter. For cell stimulation, culture medium containing the indicated concentration of recombinant human TNF-alpha , LPS, ALLN, PDTC, cycloheximide, anisomycin, or actinomycin was added to cells for the indicated time.

Northern Blot Analysis-- Total RNA was prepared from bEnd.3 cells by acid guanidinium thiocyanate/phenol/chloroform extraction (43). Northern blot analysis was performed as described (43), using previously characterized probes (37).

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

TNF-alpha -induced Expression of P-selectin in Murine Endothelial Cells Is Prevented by the Proteasome Inhibitor ALLN or the Antioxidant PDTC but Superinduced by the Translation Inhibitor Cycloheximide or Anisomycin-- In the preceding paper (38), we showed that TNF-alpha or LPS requires the sequences from -593 to -474 and from -229 to -13 in the 5'-flanking region of the murine P-selectin gene to induce expression of a reporter gene in transfected endothelial cells. Inspection of these regions revealed several putative kappa B elements and a variant ATF/CRE site, suggesting that NF-kappa B/Rel proteins and ATF-2/c-Jun heterodimers may participate in inducible expression. As an initial test of this hypothesis, we used the proteasome inhibitor ALLN or the antioxidant PDTC that blocks activation of NF-kappa B, and the translation inhibitor cycloheximide or anisomycin that prevents resynthesis of Ikappa B-alpha and activates JNK/p38 MAP kinases (44-46). We incubated murine bEnd.3 endothelioma cells with TNF-alpha or LPS in the absence or presence of a pharmacologic agent for various times. Levels of P-selectin mRNA from each group of cells were then measured by Northern blot analysis.

As demonstrated previously (36, 37), P-selectin mRNA was detected in unstimulated bEnd.3 cells, and the mRNA level was markedly increased in cells treated with TNF-alpha for 4 h (Fig. 1A). The proteasome inhibitor ALLN or the antioxidant PDTC prevented the TNF-alpha -induced increase of P-selectin mRNA but did not affect the levels of mRNA for CHO-B, a constitutively expressed transcript that is not affected by TNF-alpha or LPS (37, 47). By contrast, the translation inhibitor cycloheximide superinduced P-selectin mRNA levels in cells stimulated with TNF-alpha (Fig. 1B) or LPS (data not shown). Actinomycin D blocked the induction or superinduction of P-selectin mRNA, which verified that TNF-alpha or LPS induced expression of P-selectin mRNA through a transcriptional mechanism. The translation inhibitor anisomycin, which also activates JNK/p38 MAP kinases, elicited the same superinduction of P-selectin mRNA (data not shown). These data are consistent with the notion that activation of NF-kappa B/Rel proteins and JNK/p38 MAP kinases may participate in TNF-alpha - or LPS-induced expression of the murine P-selectin gene.


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 1.   The proteasome inhibitor ALLN or the antioxidant PDTC prevents, whereas the translation inhibitor cycloheximide superinduces, TNF-alpha -induced expression of P-selectin in bEnd.3 cells. A, confluent bEnd.3 cells were preincubated for 1 h in the presence or absence of 25 mM ALLN or 50 mM PDTC. The cells were then incubated for 4 h with TNF-alpha (100 units/ml) in the continued presence of the respective pharmacologic agent. Total RNA was isolated and analyzed by Northern blotting with labeled cDNA probes for murine P-selectin or CHO-B. B, confluent bEnd.3 cells were incubated in the presence or absence of TNF-alpha (100 units/ml), cycloheximide (CHX, 10 µg/ml), and/or actinomycin D (Act. D, 5 µg/ml). After the indicated time, total RNA was isolated and analyzed by Northern blotting as in A.

Characterization of Two Tandem kappa B Sites and a Reverse-oriented kappa B Site in the Murine P-selectin Promoter-- To identify sites for binding to NF-kappa B/Rel proteins, we synthesized double-stranded oligonucleotide probes encompassing each putative kappa B site from -593 to -13 in the 5'-flanking region of the murine P-selectin gene (Fig. 2A). Each labeled probe was assessed for binding to nuclear proteins from endothelial cells incubated with or without LPS or TNF-alpha .


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 2.   The two tandem kappa B sites in the murine P-selectin gene, but not the corresponding region of the human P-selectin gene, bind to inducible nuclear proteins in a kappa B-dependent manner. A, sequence comparisons among selected kappa B sites. The putative kappa B motifs in each sequence are in boldface, and the mutated nucleotides are in italics. The numbering of the sequences derived from the murine P-selectin gene is relative to the translation start site. The listed sequences also encode the upper strands of the oligonucleotides used as probes and competitors in gel shift assays. B, the labeled tandem kappa B probe from the murine P-selectin gene was incubated with nuclear extracts from bEnd.3 cells incubated in the absence or presence of TNF-alpha or LPS for 6 h or with nuclear extracts from BAEC incubated in the absence or presence of TNF-alpha for 3 h. The arrow marks the position of the major inducible DNA-protein complex. Inducible complexes of more rapid mobility are also present; these complexes were less consistently observed and may represent degradation products. C, the labeled tandem kappa B probe was incubated with nuclear extracts from TNF-alpha -stimulated bEnd. Three cells in the absence or presence of a 100-fold excess of an unlabeled oligonucleotide encoding the probe itself, the murine H-2Kb kappa B element (48), or the corresponding region in the 5'-flanking region of the human P-selectin gene. D, the wild-type or mutant P-selectin tandem kappa B probe was incubated with nuclear extracts from TNF-alpha -stimulated BAEC in the absence or presence of a 100-fold excess of the indicated unlabeled competitor.

A labeled probe encompassing the murine P-selectin tandem kappa B elements formed a DNA-protein complex with nuclear extracts from TNF-alpha - or LPS-stimulated, but not unstimulated, bEnd.3 cells (Fig. 2B). The labeled probe also formed a complex of identical mobility with extracts from TNF-alpha -stimulated but not unstimulated BAEC. Complex formation was sequence-specific, as it was prevented by addition of a 100-fold molar excess of the unlabeled probe, but not of a 100-fold excess of a probe containing the corresponding sequence from the human P-selectin gene (Fig. 2C). Complex formation required the kappa B elements, because it was prevented by addition of a 100-fold excess of an unlabeled kappa B probe from the murine H-2Kb gene (48). Furthermore, a murine P-selectin tandem kappa B probe with mutations in the kappa B elements failed to bind to inducible proteins (Fig. 2D).

A labeled probe containing the reverse-oriented kappa B element formed a TNF-alpha - or LPS-inducible DNA-protein complex with nuclear extracts from BAEC and bEnd.3 cells (Fig. 3A). Again, complex formation was sequence-specific, as it was prevented by addition of a 100-fold excess of the unlabeled probe but not of a probe containing the corresponding sequence from the human P-selectin gene. Binding required the kappa B sequence, because it was prevented by addition of a 100-fold excess of the unlabeled H-2Kb kappa B sequence or by introduction of mutations into the reverse-oriented kappa B site (Fig. 3B).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 3.   The reverse-oriented kappa B element in the murine P-selectin gene, but not the corresponding region of the human gene, binds to inducible nuclear proteins in a kappa B-dependent manner. A, in the left panel, the labeled reverse-oriented kappa B probe was incubated with nuclear extracts from bEnd.3 cells incubated in the absence or presence of TNF-alpha or LPS for 3 h. In the right panel, the labeled probe was incubated with nuclear extracts from BAEC incubated in the absence or presence of TNF-alpha or LPS for 6 h. B, the labeled wild-type or mutant reverse-oriented kappa B probe was incubated with nuclear extracts from BAEC stimulated with TNF-alpha in the absence or presence of a 100-fold excess of the indicated unlabeled competitor.

Probes encompassing four other putative kappa B sites (termed sequence I to IV, respectively) were tested for binding to nuclear proteins from unstimulated or TNF-alpha -stimulated BAEC. The sequence I probe formed a specific DNA-protein complex with extracts from TNF-alpha -stimulated but not unstimulated BAEC. The mobility of the complex was identical to that formed with the tandem kappa B elements, but the labeling intensity was much weaker under the same experimental conditions. The sequence II, III, and IV probes did not form detectable complexes.

To identify the proteins in these inducible complexes, we preincubated nuclear extracts from TNF-alpha -stimulated BAEC or bEnd.3 cells with antibodies to NF-kappa B/Rel proteins prior to the gel shift assay. Antibodies to p50 partially inhibited binding of nuclear proteins from TNF-alpha -stimulated BAEC to the tandem kappa B probe (Fig. 4A) or the sequence I probe (data not shown). Antibodies to p65 eliminated binding of nuclear proteins to the labeled tandem kappa B probe. In contrast, antibodies to p52, c-Rel, or RelB had no effect on binding (Fig. 4A). Antibodies to p65, but not to p50 or other proteins, prevented binding of nuclear proteins from TNF-alpha -stimulated BAEC or bEnd.3 cells to the reverse-oriented kappa B probe (Fig. 4B). These data indicate that the tandem kappa B elements bind to both p50/p65 heterodimers and p65 homodimers, whereas the reverse-oriented kappa B site binds preferentially to p65 homodimers. Sequence I binds to NF-kappa B heterodimers and p65 homodimers but with apparently low affinity.


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 4.   The two tandem kappa B elements in the murine P-selectin gene bind to NF-kappa B heterodimers and p65 homodimers, whereas the reverse-oriented kappa B element binds preferentially to p65 homodimers. A, the labeled P-selectin tandem kappa B probe was incubated with nuclear extracts from BAEC stimulated with TNF-alpha in the absence or presence of the indicated antibodies. B, the labeled P-selectin reverse-oriented kappa B probe was incubated with nuclear extracts from bEnd.3 cells or BAEC stimulated with TNF-alpha in the absence or presence of the indicated antibodies.

Characterization of a Variant ATF/CRE in the Murine P-selectin Promoter-- A putative ATF/CRE in the murine P-selectin promoter is identical in sequence to the ATF/CRE in the E-selectin gene and deviates one nucleotide from the CRE consensus sequence (27, 28, 49). To test whether the P-selectin ATF/CRE competes with the other two elements for binding to common nuclear proteins, we synthesized oligonucleotide probes encompassing the murine P-selectin ATF/CRE, the human E-selectin ATF/CRE, or a CRE consensus sequence (Fig. 5A). A labeled probe encompassing the P-selectin ATF/CRE formed a DNA-protein complex when incubated with extracts from unstimulated bEnd.3 cells (Fig. 5B) or TNF-alpha -stimulated bEnd.3 cells (data not shown). Relatively little complex formation was detected, consistent with a possibly lower affinity of the variant ATF/CRE for nuclear proteins. Complex formation was sequence-specific, as it was prevented by addition of a 100-fold molar excess of the unlabeled probe but not of an unrelated GATA element. Complex formation also required the ATF/CRE sequence, because it was prevented by addition of a 100-fold excess of an unlabeled probe encoding the E-selectin ATF/CRE or a CRE consensus sequence. The labeled CRE consensus sequence probe formed two complexes, A and B, when incubated with nuclear extracts from bEnd.3 cells (Fig. 5C). Formation of each complex was sequence-specific, as it was prevented by addition of a 50-200-fold excess of the unlabeled probe. Formation of complex A but not B was significantly diminished by addition of a 50-200-fold excess of an unlabeled probe encoding the P-selectin or E-selectin ATF/CRE. An unlabeled probe containing mutations in the murine P-selectin ATF/CRE or a probe containing the corresponding sequence from the human P-selectin gene did not inhibit complex formation (Fig. 5C). These data suggest that the murine P-selectin ATF/CRE, the E-selectin ATF/CRE, and a CRE consensus sequence bind to common nuclear factors in complex A. 


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 5.   The variant ATF/CRE in the murine P-selectin (mP-sel) gene competes with the human E-selectin (hE-sel) ATF/CRE and a CRE consensus sequence for binding ATF-2 and other nuclear proteins. A, comparisons among selected ATF/CRE (27, 28). The ATF/CRE sites are in boldface, and the mutated bases are in italics. The listed sequences also encode the upper strands of the oligonucleotides used as probes or competitors in gel shift assays. B, the labeled murine P-selectin ATF/CRE probe was incubated with bEnd.3 nuclear extracts in the absence or presence of a 100-fold excess of the indicated competitor. The arrow indicates the specific DNA-protein complex formed. C, the labeled CRE consensus sequence probe was incubated with bEnd.3 nuclear extracts in the absence or presence of a 50-200-fold excess of the indicated competitor. D, the labeled CRE consensus sequence probe was incubated with bEnd.3 nuclear extracts in the absence or presence of the indicated antibodies.

Complex A was previously demonstrated to contain the protein ATF-2 in nuclear extracts from other cells (50). To confirm that complex A from bEnd.3 cell nuclear extracts contained ATF-2, we preincubated bEnd.3 extracts with antibodies to ATF-2, c-Jun, or other nuclear proteins prior to the gel shift assay. As shown in Fig. 5D, preincubation with antibodies to ATF-2, but not to c-Jun, c-Fos, p50, or p65, significantly diminished formation of complex A. These data indicate that the murine P-selectin ATF/CRE, the E-selectin ATF/CRE, and a CRE consensus sequence bind to ATF-2 in bEnd.3 cells.

The Tandem kappa B Sites, the Reverse-oriented kappa B Site, and the Variant ATF/CRE Are Required for TNF-alpha or LPS to Maximally Induce Expression of a Reporter Gene Driven by the Murine P-selectin Promoter in Transfected Endothelial Cells-- To determine whether the tandem kappa B sites, the reverse-oriented kappa B site, and the variant ATF/CRE allowed TNF-alpha or LPS to induce expression of murine P-selectin, we mutated these elements, individually or in combination, in a reporter construct driven by the murine P-selectin promoter. The mutations were the same as those made in the mutant probes that eliminated binding to nuclear proteins. Following transfection of the wild-type construct or each mutant construct into BAEC, the cells were incubated in the absence or presence of TNF-alpha or LPS for 4.5 h and then harvested for assay of luciferase activity. Mutations in each individual element decreased TNF-alpha - or LPS-induced expression by 20-60% relative to that of the wild-type construct (Fig. 6). Combined mutations in the reverse-oriented kappa B site and the variant ATF/CRE or in all three elements further decreased, but did not abolish, TNF-alpha - or LPS-induced expression. These data demonstrate that the tandem kappa B sites, the reverse-oriented kappa B site, the variant ATF/CRE, and still uncharacterized elements are required for TNF-alpha or LPS to maximally induce expression of a murine P-selectin reporter gene in transfected endothelial cells.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 6.   Mutations in the kappa B sites and/or the ATF/CRE decrease TNF-alpha - or LPS-inducible expression, but not constitutive expression, of a reporter gene driven by the murine P-selectin promoter. The same mutations that decreased the nuclear binding activities of the indicated regulatory elements were introduced individually or in combination into a reporter gene driven by the -1392 to -13 sequence of the murine P-selectin gene. The mutant or wild-type reporter constructs were transfected into BAEC. After 40 h, the transfected cells were incubated for 4.5 h with fresh medium in the absence or presence of TNF-alpha (100 units/ml) or LPS (1 µg/ml) and then harvested for assay of luciferase activity. The data represent the mean ± S.D. of one experiment with three independent transfections. Similar results were obtained in two other experiments.

A Reporter Gene Driven by the Murine P-selectin 5'-Flanking Region Recapitulates Post-inductional Repression-- Since translocation of p65-containing NF-kappa B/Rel proteins into the nucleus is transient because of feedback inhibition by newly synthesized Ikappa B proteins (20, 21), NF-kappa B-dependent transcription usually declines after its initial induction. We measured the activity of a luciferase reporter gene driven by the murine P-selectin promoter in transfected BAEC that were stimulated with TNF-alpha for various times. Because luciferase protein and mRNA levels turn over rapidly, the kinetics of luciferase activity accurately reflect the kinetics of transcriptional activity of the reporter gene (51). Luciferase activity increased at 3 h, reached a maximum at 4.5 h, then declined rapidly and returned to a basal level by 13 h (Fig. 7). These data are consistent with post-inductional repression of transcription of the murine P-selectin gene.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 7.   Postinductional repression of transcription of a reporter gene driven by the murine P-selectin promoter. BAEC were transfected with a reporter gene driven by the -1379 to -13 sequence of the murine P-selectin gene. After 40 h, the transfected cells were incubated with culture medium in the absence or presence of TNF-alpha (100 units/ml) for the indicated time and then harvested for assay of luciferase activity. The data represent the mean ± S.D. of one experiment with three independent transfections. Similar results were obtained in another experiment.

Co-overexpression of p50 and p65 Augments kappa B-dependent Expression of a Reporter Gene Driven by the Murine P-selectin Promoter-- To test directly the role of NF-kappa B/Rel proteins in inducing expression of murine P-selectin, we co-transfected BAEC with plasmids encoding the NF-kappa B/Rel protein p50 or p65 with a reporter gene driven by the wild-type P-selectin promoter or the promoter with mutations in the kappa B and ATF/CRE. Co-expression of p50 alone slightly decreased promoter activity of the wild-type or mutant construct. However, co-expression of increasing amounts of p65 with a fixed concentration of p50 markedly increased promoter activity of the wild-type construct but not of the mutant construct (Fig. 8). Co-expression of p65 alone also increased expression of the wild-type reporter gene, but to a lesser extent than that elicited by co-expression of p65 with p50 (data not shown). These data demonstrate that p65-containing NF-kappa B/Rel proteins regulate kappa B-dependent expression of the murine P-selectin gene.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 8.   Co-expression of p50 and p65 increases murine P-selectin promoter activity in a kappa B-dependent manner. BAEC were transfected with 5 µg of a reporter gene driven by the murine P-selectin promoter with the wild-type sequence or the indicated mutations, along with the indicated amount of expression plasmids encoding p50 or p65. After 48 h, the transfected cells were harvested for assay of luciferase activity. The data represent the mean ± S.D. of one experiment with three independent transfections. Similar results were obtained in another experiment.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

We identified and characterized two tandem kappa B sites, a reverse-oriented kappa B site and a variant ATF/CRE site, that are required for TNF-alpha or LPS to optimally induce expression of the murine P-selectin gene. The presence of these elements in the murine, but not human, P-selectin gene may help explain why TNF-alpha or LPS increases expression of P-selectin in murine, but not in human, endothelial cells.

In contrast to the unique kappa B site in the human P-selectin gene that binds p50 or p52 homodimers (15, 42), the three kappa B sites in the murine gene bind inducible p65-containing NF-kappa B/Rel proteins. The unique kappa B site in the human gene is required for optimal constitutive expression of a reporter gene in transfected endothelial cells (15). In contrast, the three kappa B sites in the murine gene are important for TNF-alpha - or LPS-inducible gene expression but not for constitutive expression. The interactions of p50 or p52 homodimers with the proto-oncoprotein, Bcl-3, regulate the activity of the human kappa B site (15), whereas p65-containing NF-kappa B/Rel proteins regulate the activity of the three murine kappa B sites. These findings indicate that distinct members of the NF-kappa B/Rel family proteins regulate transcription of the murine and human P-selectin genes. The binding of newly synthesized Ikappa Balpha to p65-containing NF-kappa B/Rel proteins may explain the post-inductional repression of reporter gene expression driven by the murine P-selectin promoter. The stabilization of Ikappa Balpha by the proteasome inhibitor ALLN or the antioxidant PDTC may prevent TNF-alpha - or LPS-induced expression of P-selectin mRNA in murine endothelial cells. In contrast, the translational inhibitors cycloheximide or anisomycin may superinduce expression by preventing the resynthesis of Ikappa Balpha .

The two tandem kappa B elements in the murine P-selectin gene bind avidly to NF-kappa B heterodimers and p65 homodimers, although they lack the typical consensus sequence for binding to NF-kappa B/Rel proteins (13, 16). However, the tandem kappa B elements have striking sequence similarity to the two tandem kappa B sites in the human or murine E-selectin genes (32-34, 52). The sequences flanking or overlapping the kappa B elements in the E-selectin gene and the murine P-selectin gene have at least three A/T-rich sequences for binding to the architectural HMG I(Y) proteins (53). In the E-selectin gene, binding of HMG I(Y) proteins to the A/T-rich sequences enhances binding of NF-kappa B heterodimers to the kappa B sites and facilitates interaction of NF-kappa B heterodimers with ATF-2/c-Jun proteins that bind to an adjacent ATF/CRE. These interactions contribute to formation of a highly organized enhanceosome (2, 32, 33). By analogy, the binding of HMG I(Y) proteins to A/T-rich sequences in the murine P-selectin gene may enhance binding of NF-kappa B to the tandem P-selectin kappa B sites and may facilitate binding of NF-kappa B to the weak kappa B element located 13 base pairs 3' to the tandem kappa B sites. Proteins binding to the P-selectin tandem kappa B sites and the A/T-rich sequences may also cooperate with other transcription factors to form an enhanceosome.

The reverse-oriented kappa B site in the murine P-selectin gene binds preferentially to p65 homodimers and is required for optimal TNF-alpha - or LPS-induced expression of a reporter gene driven by the murine P-selectin promoter. To our knowledge, this is the first reported example of an asymmetric kappa B element with an opposite orientation relative to the transcriptional start site. This element may function because it binds to symmetrical p65 homodimers that do not require a specifically oriented kappa B sequence to transactivate gene expression. The identification of this unusual kappa B site further supports the notion that p65 homodimers and NF-kappa B heterodimers have distinct biological functions (54-56).

Mutation of the variant ATF/CRE in the murine P-selectin gene eliminated binding to ATF-2 and other nuclear proteins, and it also decreased the TNF-alpha - or LPS-induced expression of a reporter gene driven by the murine P-selectin promoter. This suggests that activation of the JNK/p38 MAP kinases, which phosphorylate ATF-2, is required for TNF-alpha or LPS to optimally induce expression of P-selectin. Combined mutations of the kappa B sites and the variant ATF/CRE further decreased, but did not abolish, the TNF-alpha - or LPS-inducible expression, indicating that other regulatory elements also participate. Candidate elements include three putative AP1 sites identified in the preceding paper (38) and the low affinity kappa B site identified in this study. Deletional analysis did not reveal a role for these elements in TNF-alpha - or LPS-inducible expression of the murine P-selectin reporter gene. However, deletions may alter other regulatory elements that modulate the function of the deleted element.

TNF-alpha and LPS use strikingly similar mechanisms to induce expression of the murine P-selectin gene (this study) and the human and murine E-selectin genes (2). Both genes use kappa B sites and a variant ATF/CRE to transmit signals received from extracellular stimuli. The use of two or more signal-regulated elements may allow optimal adjustment of gene expression in response to a variety of challenges (12). The similar pathways by which TNF-alpha and LPS regulate the E-selectin gene and the murine P-selectin gene are consistent with the origin of the selectin gene family by gene duplication (57). This may partially explain the overlapping functions of P-selectin and E-selectin in the mouse (58-60). It also predicts that agents such as ultraviolet light and IL-1beta , which activate NF-kappa B or JNK/p38 kinases (2), will stimulate expression of the murine, but not the human, P-selectin gene.

Our studies have the inherent limitation that cultured endothelial cells may not contain the same transcription factors and signaling proteins found in microvascular endothelial cells in vivo. However, TNF-alpha or LPS clearly augments expression of both P- and E-selectin in murine endothelial cells in vivo (35, 36, 61, 62). By contrast, intradermal injection of LPS increases expression of E-selectin, but not P-selectin, in venules of non-human primates (63). Furthermore, E-selectin mRNA levels increase in the atria of patients after cardiopulmonary bypass, whereas P-selectin mRNA levels decline (64). These in vivo studies further support a species-specific response of the P-selectin gene to TNF-alpha , LPS, or related mediators. Thus, the mechanisms for regulating the inducible transcription of the P-selectin gene appear to have evolved from mice to humans. This species-specific fine tuning of gene expression may extend to other inflammatory mediators and adhesion molecules. For example, either IL-4 or oncostatin M induces expression of P-selectin in murine and human endothelial cells. But induced expression in human cells is delayed and requires new protein synthesis, whereas induced expression in murine cells is more rapid and does not require new protein synthesis (37).2 IL-4 suppresses the TNF-alpha -inducible expression of E-selectin in human endothelial cells (65). IL-4 prevents E-selectin expression by activating Stat6, which binds to a DNA element that overlaps one of the kappa B sites in the human E-selectin gene, thereby competitively inhibiting binding of NF-kappa B (66). The Stat6 element, however, is not conserved in the murine E-selectin gene (34), suggesting that IL-4 may not suppress TNF-alpha -inducible expression of E-selectin in mice. Therefore, distinct mechanisms may be used to regulate expression of selectin genes in different species.

Our results also suggest that the function assigned to a selectin in a particular animal model may not necessarily apply to humans. In many rodent models of inflammation, tissue injury or other insults generate thrombin, histamine, oxygen-derived radicals, or other mediators that stimulate endothelial cells to redistribute P-selectin from Weibel-Palade bodies to the cell surface (67-69). Depending on the specific challenge, TNF-alpha , IL-beta , or LPS may also be elaborated. These agents cause murine endothelial cells to increase synthesis of P-selectin, which may travel directly to the cell surface if the machinery that sorts proteins into Weibel-Palade bodies is saturated. Some models may induce expression of other cytokines such as IL-4 and oncostatin M, which can also increase synthesis of P-selectin. The relative contributions of these distinct pathways of inducible expression may be difficult to distinguish in vivo. Our data suggest that mediators that activate p65-containing NF-kappa B dimers or ATF-2-containing dimers may increase transcription of the P-selectin gene in rodents, but not in humans. Close scrutiny of the mechanisms for inducing P-selectin expression in animal models may be necessary to interpret the relevance of the findings for human biology.

    ACKNOWLEDGEMENTS

We thank Ginger Hampton for technical assistance and Dr. Craig Rosen for valuable reagents. We are grateful to Dr. James Morrissey for critical reading of the manuscript. We also thank Dr. Kenneth Jackson (Molecular Biology Resource Facility, University of Oklahoma Health Sciences Center) for synthesis of oligonucleotides.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: W. K. Warren Medical Research Institute, University of Oklahoma Health Sciences Center, 825 N.E. 13th St., Oklahoma City, OK 73104. Tel.: 405-271-6480; Fax: 405-271-3137; E-mail: rodger-mcever{at}ouhsc.edu.

1 The abbreviations used are: TNF-alpha , tumor necrosis factor-alpha ; ALLN, N-acetyl-leucinyl-leucinyl-norleucinal-H; ATF, activating transcription factor; BAEC, bovine aortic endothelial cells; CRE, cAMP response element; IL, interleukin; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharide; MAP, mitogen-activated protein; PDTC, pyrrolidine dithiocarbamate.

2 L. Yao and R. P. McEver, unpublished observations.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Collins, T. (1993) Lab. Invest. 68, 499-508[Medline] [Order article via Infotrieve]
  2. Collins, T., Read, M. A., Neish, A. S., Whitley, M. Z., Thanos, D., and Maniatis, T. (1995) FASEB J. 9, 899-909[Abstract/Free Full Text]
  3. Montgomery, K. F., Osborn, L., Hession, C., Tizard, R., Goff, D., Vassallo, C., Tarr, P. I., Bomsztyk, K., Lobb, R., Harlan, J. M., and Pohlman, T. H. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6523-6527[Abstract/Free Full Text]
  4. Iademarco, M. F., McQuillan, J. J., Rosen, G. D., and Dean, D. C. (1992) J. Biol. Chem. 267, 16323-16329[Abstract/Free Full Text]
  5. Hou, J., Baichwal, V., and Cao, Z. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11641-11645[Abstract/Free Full Text]
  6. Takeuchi, M., and Baichwal, V. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3561-3565[Abstract]
  7. Gorospe, M., Kumar, S., and Baglioni, C. (1993) J. Biol. Chem. 268, 6214-6220[Abstract/Free Full Text]
  8. Matsusaka, T., Fujikawa, K., Nishio, Y., Mukaida, N., Matsushima, K., Kishimoto, T., and Akira, S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10193-10197[Abstract]
  9. Stein, B., and Baldwin, A. S., Jr. (1993) Mol. Cell. Biol. 13, 7191-7198[Abstract]
  10. Mackman, N., Fowler, B. J., Edgington, T. S., and Morrissey, J. H. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2254-2258[Abstract]
  11. Mackman, N. (1997) Thromb. Haemostasis 78, 747-754[Medline] [Order article via Infotrieve]
  12. Hill, C. S., and Treisman, R. (1995) Cell 80, 199-211[Medline] [Order article via Infotrieve]
  13. Siebenlist, U., Franzoso, G., and Brown, K. (1994) Annu. Rev. Cell Biol. 10, 405-455[CrossRef]
  14. Parry, G. C., and Mackman, N. (1994) J. Biol. Chem. 269, 20823-20825[Abstract/Free Full Text]
  15. Pan, J., and McEver, R. P. (1995) J. Biol. Chem. 270, 23077-23083[Abstract/Free Full Text]
  16. Kunsch, C., Ruben, S. M., and Rosen, C. A. (1992) Mol. Cell. Biol. 12, 4412-4421[Abstract]
  17. Ledebur, H. C., and Parks, T. P. (1995) J. Biol. Chem. 270, 933-943[Abstract/Free Full Text]
  18. De Martin, R., Vanhove, B., Cheng, Q., Hofer, E., Csizmadia, V., Winkler, H., and Bach, F. H. (1993) EMBO J. 12, 2773-2779[Abstract]
  19. Le Bail, O., Schmidt-Ullrich, R., and Israel, A. (1993) EMBO J. 12, 5043-5049[Abstract]
  20. Sun, S. C., Ganchi, P. A., Ballard, D. W., and Greene, W. C. (1993) Science 259, 1912-1915[Medline] [Order article via Infotrieve]
  21. Brown, K., Park, S., Kanno, T., Franzoso, G., and Siebenlist, U. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2523-2536
  22. Sluss, H. K., Barrett, T., Derijard, B., and Davis, R. J. (1994) Mol. Cell. Biol. 14, 8376-8384[Abstract]
  23. Su, B., and Karin, M. (1997) Curr. Opin. Immunol. 8, 402-411[CrossRef]
  24. Gupta, S., Campbell, D., Derijard, B., and Davis, R. J. (1995) Science 267, 389-393[Medline] [Order article via Infotrieve]
  25. Gupta, S., Barret, T., Whitmarsh, A., Cavanagh, J., Sluss, H. K., Derijard, B., and Davis, R. J. (1996) EMBO J. 15, 2760-2770[Abstract]
  26. Smeal, T., Binetruy, B., Mercola, D. A., Birrer, M., and Karin, M. (1991) Nature 354, 494-496[CrossRef][Medline] [Order article via Infotrieve]
  27. Benbrook, D. M., and Jones, N. C. (1994) Nucleic Acids Res. 22, 1463-1469[Abstract]
  28. Kaszubska, W., Hooft van Huijsduijnen, R., Ghersa, P., DeRaemy-Schenk, A.-M., Chen, B. P. C., Hai, T., Delamarter, J. F., and Whelan, J. (1993) Mol. Cell. Biol. 13, 7180-7190[Abstract]
  29. Angel, P., and Karin, M. (1991) Biochim. Biophys. Acta 1072, 129-157[CrossRef][Medline] [Order article via Infotrieve]
  30. Hoffman, J. A., and Reichhart, J.-M. (1997) Trends Cell Biol. 7, 309-316[CrossRef]
  31. Sluss, H. K., Han, Z., Barrett, T., Davis, R. J., and Ip, Y. T. (1996) Genes Dev. 10, 2745-2758[Abstract]
  32. Whitley, M. Z., Thanos, D., Read, M. A., Maniatis, T., and Collins, T. (1994) Mol. Cell. Biol. 14, 6464-6475[Abstract]
  33. Lewis, H., Kaszubska, W., Delamarter, J. F., and Whelan, J. (1994) Mol. Cell. Biol. 14, 5701-5709[Abstract]
  34. Becker-Andre, M., Van Huijsduijnen, R. H., Losberger, C., Whelan, J., and Delamarter, F. (1992) Eur. J. Biochem. 206, 401-411[Abstract]
  35. Sanders, W. E., Wilson, R. W., Ballantyne, C. M., and Beaudet, A. L. (1992) Blood 80, 795-800[Abstract]
  36. Weller, A., Isenmann, S., and Vestweber, D. (1992) J. Biol. Chem. 267, 15176-15183[Abstract/Free Full Text]
  37. Yao, L., Pan, J., Setiadi, H., Patel, K. D., and McEver, R. P. (1996) J. Exp. Med. 184, 81-92[Abstract]
  38. Pan, J., Xia, L., and McEver, R. P. (1998) J. Biol. Chem. 273, 10058-10067[Abstract/Free Full Text]
  39. Ruben, S. M., Narayanan, R., Klement, J. F., Chen, C.-H., and Rosen, C. (1992) Mol. Cell. Biol. 12, 444-454[Abstract]
  40. Schreiber, E., Matthias, P., Muller, M. M., and Schaffner, W. (1989) Nucleic Acids Res. 17, 6419[Medline] [Order article via Infotrieve]
  41. Disdier, M., Morrissey, J. H., Fugate, R. D., Bainton, D. F., and McEver, R. P. (1992) Mol. Biol. Cell 3, 309-321[Abstract]
  42. Pan, J., and McEver, R. P. (1993) J. Biol. Chem. 268, 22600-22608[Abstract/Free Full Text]
  43. Johnston, G. I., Cook, R. G., and McEver, R. P. (1989) Cell 56, 1033-1044[Medline] [Order article via Infotrieve]
  44. Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T. (1994) Cell 78, 773-785[Medline] [Order article via Infotrieve]
  45. Cano, E., Hazzalin, C. A., and Mahadevan, L. C. (1994) Mol. Cell. Biol. 14, 7352-7362[Abstract]
  46. Schreck, R., Meier, B., Mannel, D. N., Droge, W., and Baeuerle, P. A. (1992) J. Exp. Med. 175, 1181-1194[Abstract]
  47. Harpold, M. M., Evans, R. M., Salditt-Georgieff, M., and Darnell, J. E. (1979) Cell 17, 1025-1035[Medline] [Order article via Infotrieve]
  48. Baldwin, A. S., Jr., and Sharp, P. A. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 723-727[Abstract]
  49. Read, M. A., Whitley, M. Z., Gupta, S., Pierce, J. W., Best, J., Davis, R. J., and Collins, T. (1997) J. Biol. Chem. 272, 2753-2761[Abstract/Free Full Text]
  50. Reimold, A. M., Grusby, M. J., Kosaras, B., Fries, J. W., Mori, R., Maniwa, S., Clauss, I. M., Collins, T., Sidman, R. L., Glimcher, M. J., and Glimcher, L. H. (1996) Nature 379, 262-265[CrossRef][Medline] [Order article via Infotrieve]
  51. Brasier, A. R., and Ron, D. (1992) Methods Enzymol. 216, 386-397[Medline] [Order article via Infotrieve]
  52. Schindler, U., and Baichwal, V. R. (1994) Mol. Cell. Biol. 14, 5820-5831[Abstract]
  53. Solomon, M. J., Strauss, F., and Varshavsky, A. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 1276-1280[Abstract]
  54. Sha, W. C., Liou, H. C., Tuomanen, E. I., and Baltimore, D. (1995) Cell 80, 321-330[Medline] [Order article via Infotrieve]
  55. Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S., and Baltimore, D. (1995) Nature 376, 167-170[CrossRef][Medline] [Order article via Infotrieve]
  56. Beg, A. A., and Baltimore, D. (1996) Science 274, 782-784[Abstract/Free Full Text]
  57. Watson, M. L., Kingsmore, S. F., Johnston, G. I., Siegelman, M. H., Le Beau, M. M., Lemons, R. S., Bora, N. S., Howard, T. A., Weissman, I. L., McEver, R. P., and Seldin, M. F. (1990) J. Exp. Med. 172, 263-272[Abstract]
  58. Labow, M. A., Norton, C. R., Rumberger, J. M., Lombard-Gillooly, K. M., Shuster, D. J., Hubbard, J., Bertko, R., Knaack, P. A., Terry, R. W., Harbison, M. L., Kontgen, F., Stewart, C. L., McIntyre, K. L., Burns, D. K., and Wolitzky, B. A. (1994) Immunity 1, 709-720[Medline] [Order article via Infotrieve]
  59. Bullard, D. C., Kunkel, E. J., Kubo, H., Hicks, M. J., Lorenzo, I., Doyle, N. A., Doerschuk, C. M., Ley, K., and Beaudet, A. L. (1996) J. Exp. Med. 183, 2329-2336[Abstract]
  60. Frenette, P. S., Mayadas, T. N., Rayburn, H., Hynes, R. O., and Wagner, D. D. (1996) Cell 84, 563-574[Medline] [Order article via Infotrieve]
  61. Hahne, M., Jäger, U., Isenmann, S., Hallmann, R., and Vestweber, D. (1993) J. Cell Biol. 121, 655-664[Abstract]
  62. Gotsch, U., Jager, U., Dominis, M., and Vestweber, D. (1994) Cell Adhesion Commun. 2, 7-14[Medline] [Order article via Infotrieve]
  63. Silber, A., Newman, W., Reimann, K. A., Hendricks, E., Walsh, D., and Ringler, D. J. (1994) Lab. Invest. 70, 163-175[Medline] [Order article via Infotrieve]
  64. Burns, S. A., DeGuzman, B. J., Newburger, J. W., Mayer, J. E., Jr., Neufeld, E. J., and Briscoe, D. M. (1995) J. Thorac. Cardiovasc. Surg. 110, 924-933[Abstract/Free Full Text]
  65. Thornhill, M. H., and Haskard, D. O. (1990) J. Immunol. 145, 865-872[Abstract/Free Full Text]
  66. Bennett, B. L., Cruz, R., Lacson, R. G., and Manning, A. M. (1997) J. Biol. Chem. 272, 10212-10219[Abstract/Free Full Text]
  67. Albelda, S. M., Smith, C. W., and Ward, P. A. (1994) FASEB J. 8, 504-512[Abstract/Free Full Text]
  68. Sharar, S. R., Winn, R. K., and Harlan, J. M. (1995) Springer Semin. Immunopathol. 16, 359-378[Medline] [Order article via Infotrieve]
  69. McEver, R. P. (1997) Glycoconj. J. 14, 585-591[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.